































TAp63 maintains adult stem cells 
 
The mysterious mechanisms that regulate aging are an 
area of active research.  The induction of senescence or 
apoptosis in stem and progenitor cells is thought to 
trigger premature organismal aging [2].  Consistent with 
this idea, we found that the TAp63-/- mice had a 
significantly shortened life span compared to its wild-
type littermates [1].  These mice exhibited phenotypes 
associated with premature aging including kyphosis, 
impaired wound healing, alopecia, epithelial and 
muscular atrophy, and chronic nephritis.  These pheno-
types suggest a critical role for TAp63 in the 
maintenance of adult stem cells in multiple epithelial 
and non-epithelial tissues.  Indeed, we found that TAp63 
maintains dermal stem cells by transcriptionally 
activating the cyclin dependent kinase inhibitor, p57, 
thereby preventing hyperproliferation of these cells 
(Figure 1A) [1,3].  Similar to the phenotype identified 
in dermal and epidermal progenitor and stem cells, 
other adult stem cells in the TAp63-/- mice may be 

































cence mechanisms that we delineated may result in a 
depletion of these stem cells and premature organismal 
aging (Figure 1B) [1]. 
 
The complex roles of the p53 family in aging 
 
Increased p53 activity has been previously implicated in 
aging [4,5].  Although some mouse models with 
increased p53 activity exhibit signs of premature aging, 
others show conflicting results [6,7].  The important 
difference between these models is the alleles of p53 
present in these mice.  The mice exhibiting signs of 
premature aging contain truncated p53 mutants [4,5] 
while those that display a normal lifespan upregulate 
p53 by other mechanisms, such as the expression of a 
p53 transgene in addition to the endogenous p53 alleles 
or a hypomorphic allele of mdm2 [6,7].  One potential 
explanation of the discrepancy in the phenotypes of 
these mice is that TAp63 interacts with point mutant 
p53 rendering TAp63 functionally inactive.   
Consequently, mice expressing mutant p53 would 
exhibit phenotypes similar to those observed in the 
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occur in the context of tumorigenesis and metastasis 
[8,9].   Mice engineered to express point mutants of p53 
in Li-Fraumeni Syndrome inactivate p63 and p73 in 
tumors by binding to them and preventing the 
transactivation of their target genes [8,9,10].  These 
mouse models exhibit a metastatic phenotype similar to 
that observed in p53+/-;p63+/- and p53+/-;p73+/- mice 
illustrating an intricate relationship between the p53 
family members [11,12].   
 
Yet, another unexplored and possible explanation is that 
expression levels of the p53 family members change in 
mice that lack one or more of the family members, i.e. 
gene compensation. Such family member compensation 
has been observed in other families of genes including 
the Rb family [13,14,15].  In mouse models expressing 
abnormally high levels of p53, TAp63 levels may be 
dampened commensurate with an increase in p53 
protein expression.  p53 protein levels are known to be 
high in mice expressing mutated versions of p53 
[8,9,10].  Thus, loss of TAp63 in these mouse models 
may again result in an acceleration of organismal aging.  
































implicated in premature aging [16,17].  Therefore, 
careful characterization of the expression of the other 
p53 family members, including the individual isoforms 
of p63 and p73, is necessary in mouse models 
expressing altered levels of p53 in order to understand 
the complex interplay and potential compensation 
between the p53 family members in processes that 
regulate longevity (Figure 1). 
 
Loss of TAp63 triggers senescence and cannot be 
reversed by concomitant loss of p53 
 
Interestingly and surprisingly, senescence triggered in 
TAp63-/- epidermal precursors is p53-independent.  In 
fact, we found a higher proportion of senescent cells in 
TAp63-/-;p53-/- epidermal cells than in those lacking 
TAp63 only, indicating that loss of p53 does not bypass 
senescence in this tissue [1].  This further indicates that 
TAp63 directly regulates senescence in epidermal 
precursor cells by transcriptionally repressing Ink4a and 
Arf as has been observed in the epidermis of mice 
deficient for p63 [1,18].    The mechanisms employed by 
TAp63 to induce senescence have important implications 
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p63 evolved to have several isoforms that can be 
divided into two categories: the TA (transactivation 
competent isoforms) and the ΔN (those that lack the 
transactivation domain).  The most highly expressed 
isoforms of p63 in the skin are the ΔNp63 isoforms, 
thus the prevailing view is that ΔNp63, and more 
specifically ΔNp63α, are the isoforms that play critical 
roles in maintaining the epidermis [19,20].  However, it 
is important to note that the TAp63 isoforms 
structurally resemble p53 and have been shown in other 
systems to be induced in response to DNA damage and 
stress [21,22].  Importantly, although TAp63 protein 
expression is undetectable in the normal epidermis, we 
found that TAp63 expression increased dramatically in 
response to stress induced by wounding, indicating that 
much like p53,  TAp63 serves to protect cells from 
damage [1].  This is a novel and unrecognized role for 
TAp63 in maintaining the dermis and the integrity of the 
epidermis.    
  
TAp63: The key to longevity?  
 
Mice lacking TAp63 also develop severe skin erosions 
that do not heal [1].  These erosions result from trauma 
or ruptured blisters that form in the majority of   
TAp63-/- mice.  The failure of these mice to 
appropriately heal their wounds results from a depletion 
of SKP cells known to be required for wound healing 
[1].  Additionally, the TAp63-/- mice exhibited patches 
where there was a diminution in the number of hair 
follicles resulting in alopecia in these mice.  Some of 
these defects are similar to those seen in patients with 
Hay–Wells syndrome or ankyloblepharon–ectodermal 
dysplasia-clefting (AEC) syndrome [23].  These pa-
tients develop alopecia and skin erosions with impaired 
wound healing indicating that the TAp63-/- mouse may 
be useful as a preclinical model to test therapies for 
these disfiguring and painful diseases. 
 
In addition, given the critical function of TAp63 in 
wound healing and hair growth, reactivation of TAp63 
in tissues of patients with degenerative diseases has 
important therapeutic implications not only in patients 
with AEC syndrome but also in those with impaired 
wound healing, like diabetes. Important areas for future 
investigation include developing models and therapies 
whereby TAp63 can be reactivated in adult dermal stem 
cells to determine whether senescence and premature 
aging can be reversed in these cells to aid in the wound 
healing process and hair regeneration.   
 
The impact of the TAp63-/-  aging phenotype on 
cancer 
 
p63 is an important suppressor of tumorigenesis and 
metastasis; however, at first glance, the role of p63 in 
senescence and aging may seem at odds with its role as 
a tumor suppressor.  It is important to note that adult 
dermal stem cells are initially hyperproliferative prior to 
acquiring a senescent phenotype (Figure 1B).   By 
extension, in tumor formation, cancer stem or precursor 
cells that lose TAp63 may likewise be hyper-
proliferative.  With the high levels of DNA damage and 
genomic instability that are detected in dermal and 
epidermal stem cells lacking TAp63  [1],  these cancer 
stem cells will likely acquire new mutations that allow 
escape from senescence, an ideal formula for tumor 
formation.  In addition to further investigation on how 
TAp63 affects cancer stem cells, the milieu in which 
cancer cells reside must also be closely examined in the 
TAp63-/- mouse model.  Cancer incidence increases 
with age, and it is possible that the prematurely aged 
environment of the TAp63-/- mouse provides an ideal 
environment for tumor formation and metastasis. 
Further investigation on the effects of premature aging 
in the TAp63 deficient mouse model on tumor formation 
is critical to obtain an understanding of the roles of 
TAp63 as a tumor suppressor gene. 
 
In summary, we have revealed a critical role for TAp63 
in preventing premature aging and further complexity of 
the p53 family, underscoring a need to understand the 
family as a whole and its roles in human diseases. A 
clear understanding of the intimate and complex 
relationship between the p53 family of genes is essential 
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